Literature DB >> 15184100

Gene-environment interplay in schizopsychotic disorders.

Tomas Palomo1, Trevor Archer, Richard M Kostrzewa, Rrichard J Beninger.   

Abstract

Genetic studies have sought to identify subtypes or endophenotypes of schizophrenia in an effort to improve the reliability of findings. A number of chromosomal regions or genes have now been shown to have had replicated linkage to schizophrenia susceptibility. Molecules involved in neurodevelopment or neurotransmitter function are coded by many of the genes that have been implicated in schizophrenia. Studies of neurotransmitter function have identified, among others, a possible role for GABA, glutamate and dopamine in animal models of schizophrenia. GABA neurons that co-express the calcium binding protein parvalbumin have been implicated as have glutamatergic metabotropic receptors and dopamine D3 receptors. Stress influences glutamate and dopamine providing another environmental factor that may interact with the influence of genes on neurotransmitter function. Neurotransmitter interactions include influences on signaling molecules and these too have been implicated in forms of learning thought to be affected in schizophrenia. Results continue to unravel the interplay of genes and environment in the etiology of schizophrenia and other psychotic disorders. Copyright 2004 FP Graham Publishing Co.

Entities:  

Mesh:

Year:  2004        PMID: 15184100     DOI: 10.1007/bf03033291

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  77 in total

1.  Developmental markers of psychiatric disorders as identified by sensorimotor gating.

Authors:  Susan B. Powell; Mark A. Geyer
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

2.  A neurodevelopmental model of schizophrenia: neonatal disconnection of the hippocampus.

Authors:  Barbara K. Lipska; Daniel R. Weinberger
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

Review 3.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

Review 4.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

Review 5.  From gene to identified neuron to behaviour in Caenorhabditis elegans.

Authors:  Catharine H Rankin
Journal:  Nat Rev Genet       Date:  2002-08       Impact factor: 53.242

6.  Neuroticism, major depression and gender: a population-based twin study.

Authors:  A Fanous; C O Gardner; C A Prescott; R Cancro; K S Kendler
Journal:  Psychol Med       Date:  2002-05       Impact factor: 7.723

Review 7.  Candidate gene studies of antipsychotic drug efficacy and drug-induced weight gain.

Authors:  Anil K Malhotra
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 8.  Calcium binding protein markers of GABA deficits in schizophrenia--postmortem studies and animal models.

Authors:  Gavin P Reynolds; Zuhal Abdul-Monim; Joanna C Neill; Zhi-Jun Zhang
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

9.  Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat.

Authors:  R S Mansbach; M A Geyer
Journal:  Neuropsychopharmacology       Date:  1989-12       Impact factor: 7.853

10.  The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy.

Authors:  P F Liddle
Journal:  Br J Psychiatry       Date:  1987-08       Impact factor: 9.319

View more
  5 in total

Review 1.  Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic labyrinths.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 2.  Neurotoxins and neurotoxicity mechanisms. An overview.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

3.  Affective status in relation to impulsive, motor and motivational symptoms: personality, development and physical exercise.

Authors:  Tomas Palomo; Richard J Beninger; Richard M Kostrzewa; Trevor Archer
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 4.  Comorbidity of substance abuse with other psychiatric disorders.

Authors:  Tomas Palomo; Trevor Archer; Richard M Kostrzewa; Richard J Beninger
Journal:  Neurotox Res       Date:  2007-07       Impact factor: 3.911

Review 5.  Genetic variation and shared biological susceptibility underlying comorbidity in neuropsychiatry.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2007-07       Impact factor: 3.911

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.